Leaflet QLAIRA film-coated tablets
Product code: W63889001 Quantity: 1
Indicated for: contraception
Route of administration: oral
Substance: estradiol valerate + dienogest (hormonal contraceptive + progestogen)
ATC: G03AB08 (Genito urinary system and sex hormones | Hormonal contraceptives for systemic use | Progestogens and estrogens, sequential preparations)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Estradiol valerate and dienogest are used together in combined hormonal treatments, primarily for hormone replacement therapy (HRT) in postmenopausal women and for the treatment of endometriosis. This combination helps balance hormone levels and alleviate symptoms associated with estrogen deficiency.
In hormone replacement therapy, estradiol valerate replaces natural estrogen, reducing menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. Dienogest, a progestin, protects the uterine lining from excessive estrogen effects, preventing endometrial hyperplasia.
This combination is also effective in treating endometriosis, reducing pelvic pain and other associated symptoms. Dienogest inhibits the growth of endometrial tissue, while estradiol helps maintain hormonal balance.
Side effects may include headaches, nausea, breast tenderness, or mood changes. In rare cases, more serious reactions such as blood clots or high blood pressure may occur, making regular medical monitoring essential.
Patients should strictly follow their doctor’s instructions, and long-term use should be periodically evaluated to minimize risks and maximize treatment benefits.
General data about QLAIRA
- Substance: estradiol valerate + dienogest
- Date of latest medicines list: 01-06-2026
- Product code: W63889001
- Pharmaceutical form: film-coated tablets
- Quantity: 1
- Product type: Original
- Price: 64.85 RON
- Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.